Boston Scientific Corporation BSX, despite industrywide macroeconomic upheavals, has been seeing strong growth momentum ...

In the past week, a Boston biotech led by longtime industry CEO Harvey Berger said it plans to shut down, while another ...

Argus raised the firm’s price target on Boston Scientific (BSX) to $130 from $105 and keeps a Buy rating on the shares. The firm sees strong ...

The tools ideate on Boston Scientific’s Farapulse PFA system, which contributed towards a 172% uptick in the company’s Q4 ...